U.S. markets closed
  • S&P Futures

    4,533.50
    +25.00 (+0.55%)
     
  • Dow Futures

    34,194.00
    +192.00 (+0.56%)
     
  • Nasdaq Futures

    15,954.50
    +84.75 (+0.53%)
     
  • Russell 2000 Futures

    2,159.20
    +12.90 (+0.60%)
     
  • Crude Oil

    65.91
    +0.34 (+0.52%)
     
  • Gold

    1,779.40
    -2.20 (-0.12%)
     
  • Silver

    22.44
    +0.11 (+0.47%)
     
  • EUR/USD

    1.1338
    +0.0015 (+0.14%)
     
  • 10-Yr Bond

    1.4340
    -0.0090 (-0.62%)
     
  • Vix

    31.12
    +3.93 (+14.45%)
     
  • GBP/USD

    1.3304
    +0.0027 (+0.20%)
     
  • USD/JPY

    113.0450
    +0.2650 (+0.23%)
     
  • BTC-USD

    57,046.03
    -144.89 (-0.25%)
     
  • CMC Crypto 200

    1,451.95
    -17.13 (-1.17%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,750.67
    -184.95 (-0.66%)
     

Recap: Orchard Therapeutics Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Orchard Therapeutics (NASDAQ:ORTX) remained unaffected after the company reported Q4 results.

Quarterly Results

Earnings per share were up 26.09% year over year to ($0.34), which beat the estimate of ($0.35).

Revenue of $0 decreased by 100.00% year over year, which missed the estimate of $60,000.

Guidance

Orchard Therapeutics hasn't issued any earnings guidance for the time being.

View more earnings on ORTX

Orchard Therapeutics hasn't issued any revenue guidance for the time being.

Price Action

52-week high: $13.09

52-week low: $3.76

Price action over last quarter: Up 59.48%

Company Description

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.